Two people wearing blue gloves and lab coats inspect a small clear vial against a dark background; one person points at the vial, indicating discussion or analysis.

PREPAREDNESS TODAY, SAFER TOMORROW.

Emergent Partners with Professional Baseball Player Davis Schneider to Raise Awareness of NARCAN® Nasal Spray Among Canadians and Help Save Lives

Star left fielder joins forces with Emergent to share his family’s story and educate the public on the importance of being prepared with NARCAN® Nasal Spray.

LEARN MORE

The New Way Forward

Who we protect will not change, but how we protect them will. Emergent is leading the new way forward for public health.

Learn more

Capabilities

We are a leading public health company that delivers protective and life-saving solutions to communities around the world.

  • We offer commercialized products that address endemic public health threats such as the opioid epidemic.

  • We specialize in developing, manufacturing, and supplying medical countermeasures for national security and public health preparedness.

  • We leverage our specialized in-house capabilities to support biopharma innovators, governments and non-government organizations with their development and manufacturing needs. ​

A person wearing a helmet and backpack stands with a bike, facing a smiling woman sitting on a bench outdoors in a park with city buildings in the background.

At Emergent, our mission is to protect and save lives.

View our 2024 Annual Report

Emergent BioSolutions Awarded Contract Modification Valued at Approximately $24 Million for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)

GAITHERSBURG, Md., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced a contract modification valued at approximately $24 million from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), to supply CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted) for anthrax preparedness efforts. Anthrax remains a significant global biological threat due to its potential use in a bioterrorism event and its implications for public health and national security.
Read More

Emergent BioSolutions Awarded Government of Canada Standing Offer for NARCAN® Nasal Spray

WINNIPEG, Manitoba, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has been awarded a standing offer by the Government of Canada, through a competitive procurement process, to supply NARCAN® Nasal Spray. The standing offer is effective from October 1, 2026, through September 30, 2029, with an option to extend for an additional two years.
Read More

Emergent BioSolutions Reinforces Commitment to Opioid Overdose Education and Preparedness on International Overdose Awareness Day

GAITHERSBURG, Md., Aug. 31, 2026 (GLOBE NEWSWIRE) -- In recognition of International Overdose Awareness Day (IOAD), Emergent BioSolutions (NYSE: EBS) is reaffirming its commitment to expanding awareness of opioid overdose risks and increasing preparedness to help save lives. According to the World Health Organization, opioids are associated with nearly 80 percent of drug-related deaths worldwide, highlighting the continued need for education, preparedness and access to life-saving interventions.i As opioid overdose remains a significant global public health challenge, Emergent is focused on empowering people with the information and tools needed to act in the event of an opioid overdose emergency.
Read More
READ ALL NEWS